VeriSIM Life develops BIOiSIM, a first-in-class AI/ML-driven 'virtual drug development engine' that models and de-risks R&D decisions to improve translatability from animals to humans. The platform aims to reduce time, cost and the need for animal testing by generating validated, physics-based models to narrow candidate selections earlier in development. VeriSIM positions BIOiSIM to help launch preclinical programs and increase the likelihood of clinical success for investigational drugs addressing high unmet needs. The company plans to scale operations, democratize access to BIOiSIM, fast-track sales and marketing, and expand transformational partnerships with industry and academia. The business highlights the platform's capacity to provide meaningful insights earlier in development, addressing the decades-old translatability problem that causes most drugs tested in animals to fail in humans. No operating metrics such as revenue or user counts were disclosed in the article. VeriSIM Life's core product is BIOiSIM, a proprietary AI- and machine learning-driven whole-body biosimulation platform designed to predict clinical efficacy and toxicity of drugs prior to human trials. The company uses the platform to translate, scale, and accelerate drug development while de-risking R&D decisions for pharma and biotech partners. With NSF support, VeriSIM is applying BIOiSIM to rapidly repurpose and optimize combinations and dosing strategies of approved and investigational drugs against COVID-19. The team says multi-targeted drug combinations may be more efficacious than single therapies given the virus's multifactorial and polygenic nature and emerging variants. VeriSIM plans to expand the platform's capabilities to enable selection and deployment of drug combinations across diseases, including rare and epidemic-prone conditions, and to build a scalable pandemic-readiness tool. Financially, the company received a $255,908 Phase I SBIR grant and is eligible to apply for a Phase II award of up to $1,000,000. VeriSIM Life develops machine-learning and engineering‑based in silico biosystem simulations that serve as 'digital' animals and, in the future, humans to improve translational research in drug development. Its platform models pharmacology through pharmacokinetic and pharmacodynamic modeling and simulation to help design better drugs, predict disease outcomes, and select patients who would benefit from therapies. The company positions these simulations as a way to reduce reliance on animal testing, lower R&D costs and timelines, and increase accuracy compared with traditional preclinical approaches. VeriSIM’s stated mission is to increase human life expectancy and personalize patient treatment by accelerating drug discovery decisions and bringing more personalized drugs to market. The company recently raised a $5.2M series seed co-led by OCA Ventures and Serra Ventures with participation from Susa Ventures, Intel Capital, Stage Venture Partners, Village Global, Twin, and Loup Ventures. With the new funding, VeriSIM plans to expand academic partnerships, optimize its models, grow engineering and operations talent, and engage more with larger pharma and biotech partners.

Total raised

$20M

Funding rounds

3

Latest round

Series A

Latest activity

Jan 2022